Immutep to Present Phase II TACTI-002 Data at SITC 2021
October 01, 2021 08:00 ET
|
Immutep Limited
Sydney, Australia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
September 29, 2021 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep to Present at Healthcare Investor Conferences
September 28, 2021 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
September 21, 2021 08:38 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
September 01, 2021 08:00 ET
|
Immutep Limited
Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Last 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of...
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
August 31, 2021 08:00 ET
|
Immutep Limited
Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for...
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
August 27, 2021 08:00 ET
|
Immutep Limited
Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no....
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
August 05, 2021 08:00 ET
|
Immutep Limited
Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for...
Immutep Quarterly Activities Report
July 13, 2021 08:00 ET
|
Immutep Limited
Immutep entered late-stage development in the newly validated LAG-3 spaceData from 1st line NSCLC and 2nd line HNSCC presented at ASCOEfti to be evaluated in new triple combination therapy trial and...
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
July 06, 2021 08:00 ET
|
Immutep Limited
Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United...